Skip to main content
Clinical Trials/NCT04016987
NCT04016987
Unknown
Not Applicable

Automated Structured Education Intervention Based on an App and Artificial Intelligence in Chinese Patients With Type 1 Diabetes

Second Xiangya Hospital of Central South University1 site in 1 country138 target enrollmentSeptember 8, 2020
ConditionsType 1 Diabetes

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Type 1 Diabetes
Sponsor
Second Xiangya Hospital of Central South University
Enrollment
138
Locations
1
Primary Endpoint
changes in serum hemoglobin A1c level
Last Updated
5 years ago

Overview

Brief Summary

In recent years, more and more attention has been paid to diabetes self-management. Glycemic control and self-management skills of patients with type 1 diabetes (T1DM) in China are poor. Artificial intelligence (AI) and the Internet offer a new way to improve the self-management skills of patients with chronic diseases. Few studies have combined AI technology with structured education intervention of type 1 diabetes. This study is innovative in that it compares the effectiveness of smartphone app between usual care, as well as automatic and individualized app education and standardized app education to explore whether the individualized treatment advocated by the latest guideline will bring any additional benefit to T1DM patients. The ultimate goal is to provide an effective and convenient approach for glycemic control of type 1 diabetes and reduce related disease burden in China.

Detailed Description

This is a single-blinded, 1:1 paralleled group cluster randomized controlled trial (RCT). The intervention will last for 24 weeks. The laboratory staff who test the HbA1c level, the outcome assessor who collects the blood glucose data, and the statisticians will be blinded to the treatment allocation. Sample size estimation: We propose to enroll 138 patients with type 1 diabetes (T1DM) by considering withdrawals, 69 in the smartphone app groups and 69 in the routine care group. Sample size estimation is based on hypothesized changes in the primary outcome HbA1c. In order to ensure high quality data, two staff are responsible for the input of original data into the database to check and confirm the accuracy. When the data entered by two staff independently, the auxiliary staff decides which data to use. Data analysis will be conducted under the intention-to-treat principle by including all the randomized patients in the data analysis. Missing data will be filled in with multiple imputation method. Any substantial difference in baseline characteristics will be adjusted with mixed-model regression analysis. Sensitivity analysis will be conducted by using per-protocol data by excluding those patients who drop out of the RCT.

Registry
clinicaltrials.gov
Start Date
September 8, 2020
End Date
December 2023
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Second Xiangya Hospital of Central South University
Responsible Party
Principal Investigator
Principal Investigator

Xia Li

Professor, Department of Endocrinology, Institute of of Metabolism and Endocrinology, Nationa Clinical Research Center for Metabolic Diseases, Second Xiangya Hospital of Central South University

Second Xiangya Hospital of Central South University

Eligibility Criteria

Inclusion Criteria

  • Individuals diagnosed with Type 1 Diabetes according to the 1999 World Health Organization report
  • Insulin dependence from disease onset
  • Aged 18-50 years
  • With a disease duration over 6 months
  • With a HbA1c level over 7%
  • Treated T1DM with multiple daily injections or insulin pump
  • Individuals who own smartphone and are capable of using wechat or apps

Exclusion Criteria

  • Age below 18 years or above 50 years
  • Being pregnant
  • With mental disorders
  • Have any other condition or disease that may hamper from compliance with the protocol or complication of the trial
  • Already using a smartphone app for managing diabetes
  • Having chronic complications including diabetic retinopathy, diabetic nephropathy or diabetic foot, diabetic neuropathy

Outcomes

Primary Outcomes

changes in serum hemoglobin A1c level

Time Frame: from baseline to week 12, 24

A1c reflects the average blood glucose level in the past 2-3 months.

Secondary Outcomes

  • Diastolic blood pressure(from baseline to week 12, 24)
  • changes in Time in range (TIR)(from baseline to week 12, 24)
  • Chinese version of Diabetes Quality of Life scale(from baseline to week 12, 24)
  • Diabetes Empowerment Scale-Short Form(from baseline to week 12, 24)
  • State-Trait Anxiety Inventory (STAI)(from baseline to week 12, 24)
  • Total cholesterol(from baseline to week 12, 24)
  • Low-density lipoprotein (LDL) cholesterol(from baseline to week 12, 24)
  • Height in meters(from baseline to week 12, 24)
  • Patients engagement with the app(automatically collected by the app from baseline to week 24)
  • Fasting blood glucose(from baseline to week 12, 24)
  • Adverse events(every 4 weeks from baseline to week 24)
  • Diabetes Self-Management Scale(from baseline to week 12, 24)
  • Chinese version of Diabetes Self-Care Activities(from baseline to week 12, 24)
  • Beck's Depression Inventory (BDI)(from baseline to week 12, 24)
  • High-density lipoprotein (HDL) cholesterol(from baseline to week 12, 24)
  • Triglycerides(from baseline to week 12, 24)
  • Systolic blood pressure(from baseline to week 12, 24)
  • Weight in kilograms(from baseline to week 12, 24)

Study Sites (1)

Loading locations...

Similar Trials